ストックスクリーナーアプリを入手
3.79
0.52%
-0.02
アフターアワーズ：
3.83
0.04
+1.06%
前日終値:
$3.81
開ける：
$3.71
24時間の取引高:
3.20M
Relative Volume:
0.73
時価総額：
$1.34B
収益：
$6.23M
当期純損益:
$-95.90M
株価収益率:
-9.7179
EPS:
-0.39
ネットキャッシュフロー:
$-68.47M
1週間 パフォーマンス:
-13.47%
1か月 パフォーマンス:
-19.87%
6か月 パフォーマンス:
-17.43%
1年 パフォーマンス:
+116.57%
1日の値動き範囲:
$3.70
$3.95
1週間の範囲:
$3.63
$4.42
52週間の値動き範囲:
$1.11
$5.465
Precigen Inc Stock (PGEN) Company Profile
名前
Precigen Inc
セクター
電話
301-556-9900
住所
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
3.79 | 1.35B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-15 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-03-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 開始されました | JP Morgan | Neutral |
| 2022-11-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 開始されました | Stifel | Buy |
| 2021-02-22 | 開始されました | Wells Fargo | Overweight |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-05-08 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Precigen Inc (PGEN) 最新ニュース
Aug Update: Can Precigen Inc beat the S P 5002025 Winners & Losers & Safe Capital Growth Tips - baoquankhu1.vn
Precigen, Inc. Hits Day Low of $4.04 Amid Price Pressure - Markets Mojo
Precigen, Inc. Experiences Evaluation Revision Amidst Mixed Market Performance Indicators - Markets Mojo
Precigen, Inc. (PGEN): Investor Outlook On A Biotech With 88% Potential Upside - DirectorsTalk Interviews
Why analysts remain bullish on Precigen Inc. stockMarket Growth Report & Advanced Technical Analysis Signals - mfd.ru
Key Takeaways - StocksToTrade
Precigen (NASDAQ:PGEN) Shares Down 6%What's Next? - MarketBeat
Strategic Moves Boost PGEN Momentum Amidst Market Shifts - StocksToTrade
Precigen (NASDAQ:PGEN) Hits New 12-Month HighHere's What Happened - MarketBeat
Can Precigen Translate PAPZIMEOS Momentum Into Revenue Growth And Shareholder Gains? - RTTNews
Precigen (NASDAQ:PGEN) Trading 5.2% HigherStill a Buy? - MarketBeat
Precigen stock hits 52-week high at 5.23 USD - Investing.com
Commit To Buy Precigen At $4, Earn 26.2% Using Options - Nasdaq
Precigen stock hits 52-week high at 5.23 USD By Investing.com - Investing.com UK
3 High Growth Companies With Strong Insider Ownership - simplywall.st
Will Precigen Inc. stock maintain growth story2025 Volatility Report & Daily Stock Trend Reports - mfd.ru
What are Precigen Inc.’s recent SEC filings showingJuly 2025 Update & Reliable Entry Point Trade Alerts - mfd.ru
Macro Review: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Fed Impact & Verified Chart Pattern Signals - baoquankhu1.vn
Why Precigen Inc. stock remains on watchlistsJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - mfd.ru
Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support - Finviz
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Promising 79% Upside Potential in Biotechnology - DirectorsTalk Interviews
Goldman Sachs Penny Stocks: Top 12 Stock Picks - Insider Monkey
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Standard Of Care Endorsement - Sahm
Gains Recap: Is Planet Labs PBC stock a buy or sell2025 Market Outlook & Daily Growth Stock Tips - baoquankhu1.vn
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech (NASDAQ:PGEN) - Seeking Alpha
What are Precigen Inc.’s growth levers2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Risk Hedge: What is the dividend yield of Precigen IncJuly 2025 Closing Moves & Weekly Top Gainers Trade List - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: Unpacking The 100% Upside Potential - DirectorsTalk Interviews
Market Trends: Is Precigen Inc stock risky to hold nowTrade Ideas & Community Shared Stock Ideas - baoquankhu1.vn
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy - simplywall.st
AI Stocks: Can Bioceres Crop Solutions Corp outperform under higher oil pricesMarket Trend Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: 87% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th - Nasdaq
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Potential 75% Upside in the Biotech Sector - DirectorsTalk Interviews
Market Pulse: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next - simplywall.st
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN - MarketBeat
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - Finviz
New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest - MarketBeat
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - Sahm
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
Precigen Inc (PGEN) 財務データ
収益
当期純利益
現金流量
EPS
1.18%
0.45%
大文字化:
|
ボリューム (24 時間):